A citation-based method for searching scientific literature

Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
Times Cited: 259



Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Lancet 2019
Times Cited: 916




List of shared articles



Times cited



Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
Davide Margonato, Giuseppe Galati, Simone Mazzetti, Rosa Cannistraci, Gianluca Perseghin, Alberto Margonato, Andrea Mortara. Heart Fail Rev 2021
5

Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.
Adriana Marton, Tatsuroh Kaneko, Jean-Paul Kovalik, Atsutaka Yasui, Akira Nishiyama, Kento Kitada, Jens Titze. Nat Rev Nephrol 2021
13

Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials.
Francisca Dos Santos Coelho, Marta Borges-Canha, Madalena von Hafe, João Sérgio Neves, Catarina Vale, Ana Rita Leite, Davide Carvalho, Adelino Leite-Moreira. Diabetes Metab Res Rev 2021
5

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
3

SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial.
Katrine M Lauritsen, Bent R R Nielsen, Lars P Tolbod, Mogens Johannsen, Jakob Hansen, Troels K Hansen, Henrik Wiggers, Niels Møller, Lars C Gormsen, Esben Søndergaard. Diabetes 2021
5

SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.
Xiaodan Wang, Jingyu Ni, Rui Guo, Lan Li, Jing Su, Feng He, Guanwei Fan. Heart Fail Rev 2021
0

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
6

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Hang-Long Li, Gregory Y H Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-Zhen Wu, Qing-Wen Ren, Hung-Fat Tse, Bernard-M Y Cheung, Kai-Hang Yiu. Cardiovasc Diabetol 2021
5

An evaluation of canagliflozin for the treatment of type 2 diabetes: an update.
Taichi Minami, Akiko Kameda, Yasuo Terauchi. Expert Opin Pharmacother 2021
0

Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, Bruno Tassone, Roberta Pujia, Marco Ricchio, Raffaele Serra, Angela Sciacqua, Ashour Michael, Michele Andreucci,[...]. Front Med (Lausanne) 2021
0

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
0

Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient.
Vasilios Kotsis, Jens Jordan, Stella Stabouli, Christina Antza, Dragan Micic, Bojan Jelaković, Markus P Schlaich, Peter M Nilsson, Reinhold Kreutz, Giuseppe Mancia,[...]. J Hypertens 2020
1


Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Metab Syndr Obes 2020
27


Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.
Dulce Brito, Paulo Bettencourt, Davide Carvalho, Jorge Ferreira, Ricardo Fontes-Carvalho, Fátima Franco, Brenda Moura, José Carlos Silva-Cardoso, Rachel Tavares de Melo, Cândida Fonseca. Cardiovasc Drugs Ther 2020
2

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Ona Kinduryte Schorling, Douglas Clark, Isabella Zwiener, Stefan Kaspers, Jisoo Lee, Hristo Iliev. Adv Ther 2020
4

Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment.
Erasmia Sampani, Pantelis Sarafidis, Aikaterini Papagianni. Expert Opin Drug Saf 2020
4


Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Petar M Seferović, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D Anker, Robin Ray, Yuksel Çavuşoğlu,[...]. Eur J Heart Fail 2020
26

Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, Francesco Spannella. Nutr Metab Cardiovasc Dis 2020
3


Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020
1

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
Antonios Douros, Lisa M Lix, Michael Fralick, Sophie Dell'Aniello, Baiju R Shah, Paul E Ronksley, Éric Tremblay, Nianping Hu, Silvia Alessi-Severini, Anat Fisher,[...]. Ann Intern Med 2020
22